Zhong Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zhong Zheng has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Hongjie You
Department of Urology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China
1 shared publication - Hui Zhang
Department of Urology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China
1 shared publication - Jiabei Jin
Department of Biochemistry and Molecular Biology, Health Science Center, Ningbo University, Ningbo, Zhejiang, China
1 shared publication - Jinhui Li
Department of Urology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China
1 shared publication - Liangpei Wu
Department of Ultrasound Medicine, The Affiliated People’s Hospital of Ningbo University, Ningbo, Zhejiang, China
1 shared publication - Lili Kong
Department of Biochemistry and Molecular Biology, Health Science Center, Ningbo University, 818 Fenghua Road, Ningbo 315211, China
1 shared publication
Latest Publications
- Open Access
- 4 March 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (8)
SPOP mutations increase PARP inhibitor sensitivity via CK2/PIAS1/SPOP axis in prostate cancer
It is well documented that impaired DNA damage repair (DDR) induces genomic instability that can efficiently increase the sensitivity of prostate cancer (PCa) cells to PARP inhibitors; however, the underlying mechanism remains elusive. Here, we found profound genomic instability in PCa cells with SPOP gene mutations and confirmed the sensitivity of SPOP -mutated PCa cells to olaparib-induced apoptosis. Mechanistically, we identified olaparib-induced CK2-mediated phosphorylation of PIAS1-S468, which in turn mediated SUMOylation of SPOP, thus promoting its E3 ligase activity in the DDR. Moreover, an abnormal CK2/PIAS1/SPOP axis due to SPOP mutations or defects in CK2-mediated phosphorylation of PIAS1, as well as SPOP inhibitor treatment, led to impaired DDR, thus increasing olaparib-induced apoptosis of PCa cells and enhancing olaparib sensitivity in animal models and patient-derived organoids. This suggested that disruption of the CK2/PIAS1/SPOP signaling axis could serve as an indicator for targeted therapy of PCa using a PARP inhibitor.
- 4 March 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (8)
Open AccessSPOP mutations increase PARP inhibitor sensitivity via CK2/PIAS1/SPOP axis in prostate cancer
It is well documented that impaired DNA damage repair (DDR) induces genomic instability that can efficiently increase the sensitivity of prostate cancer (PCa) cells to PARP inhibitors; however, the underlying mechanism remains elusive. Here, we found profound genomic instability in PCa cells with SPOP gene mutations and confirmed the sensitivity of SPOP -mutated PCa cells to olaparib-induced apoptosis. Mechanistically, we identified olaparib-induced CK2-mediated phosphorylation of PIAS1-S468, which in turn mediated SUMOylation of SPOP, thus promoting its E3 ligase activity in the DDR. Moreover, an abnormal CK2/PIAS1/SPOP axis due to SPOP mutations or defects in CK2-mediated phosphorylation of PIAS1, as well as SPOP inhibitor treatment, led to impaired DDR, thus increasing olaparib-induced apoptosis of PCa cells and enhancing olaparib sensitivity in animal models and patient-derived organoids. This suggested that disruption of the CK2/PIAS1/SPOP signaling axis could serve as an indicator for targeted therapy of PCa using a PARP inhibitor.